Amoéba
Develops natural microbiological solutions to manage bacterial and fungal risks.
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other chemical products
Description
Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-08 08:00 |
AMOEBA : Déclaration du nombre total de droits de vote et du nombre d’actions c…
|
French | 259.0 KB | ||
| 2024-01-08 08:00 |
AMOEBA CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
|
French | 284.3 KB | ||
| 2024-01-05 18:00 |
AMOEBA : Bilan semestriel du contrat de liquidité
|
French | 441.6 KB | ||
| 2023-12-15 17:45 |
AMOEBA: Commercial strategy and governance further strengthened and industrial …
|
English | 356.2 KB | ||
| 2023-12-15 17:45 |
AMOEBA : Renforcement de la Gouvernance, de la stratégie commerciale et décalag…
|
French | 353.3 KB | ||
| 2023-11-23 17:45 |
AMOEBA : Une année de tests en champs qui confirme le positionnement stratégiqu…
|
French | 1.6 MB | ||
| 2023-11-23 17:45 |
AMOEBA : A year of field trials that confirms AXPERA's strategic positioning
|
English | 809.3 KB | ||
| 2023-10-27 17:45 |
AMOEBA : MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2O23
|
French | 314.8 KB | ||
| 2023-10-18 17:45 |
AMOEBA : Publication d’un article scientifique présentant l’efficacité de ses p…
|
French | 4.1 MB | ||
| 2023-10-18 17:45 |
AMOEBA: Publication of a scientific paper concerning the efficacy of its biocon…
|
English | 4.1 MB | ||
| 2023-10-16 17:45 |
AMOEBA : Des résultats probants pour une utilisation du lysat de Willaertia mag…
|
French | 511.1 KB | ||
| 2023-10-16 17:45 |
AMOEBA : Convincing results for the use of Willaertia magna C2c Maky lysate in …
|
English | 513.1 KB | ||
| 2023-10-12 08:55 |
AMOEBA annonce le démarrage des travaux de son usine biocontrôle USIBIAM à Cava…
|
French | 1.7 MB | ||
| 2023-10-12 08:55 |
AMOEBA announces the beginning of construction of its USIBIAM biocontrol plant …
|
English | 3.4 MB | ||
| 2023-10-05 18:00 |
Amoéba : un premier semestre marqué principalement par le développement du proj…
|
French | 413.4 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Amoéba
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | N/A | Other | Buy | 6,300 | 3,609.90 EUR |
| 2024-08-29 | N/A | Other | Sell | 5,500 | 3,564.00 EUR |
| 2024-08-28 | N/A | Other | Buy | 3,200 | 1,782.08 EUR |
| 2024-08-27 | N/A | Other | Buy | 20,049 | 11,231.45 EUR |
| 2024-08-26 | N/A | Other | Buy | 31,107 | 17,441.69 EUR |
| 2024-08-22 | N/A | Other | Buy | 2,255 | 1,298.88 EUR |
| 2024-08-20 | N/A | Other | Buy | 16,664 | 8,838.59 EUR |
| 2024-08-19 | N/A | Other | Buy | 13,390 | 6,795.43 EUR |
| 2024-08-16 | N/A | Other | Buy | 6,745 | 3,468.28 EUR |
| 2024-08-09 | N/A | Other | Buy | 40,748 | 21,559.77 EUR |
Peer Companies
